Foundation Medicine and Relay Therapeutics Announce Collaboration

Foundation Medicine and Relay Therapeutics announced a collaboration to develop FoundationOne®CDx as a companion diagnostic for RLY-4008, the company’s investigational FGFR2 inhibitor.

RLY-4008 is a selective oral small molecule inhibitor of FGFR2, which is currently being evaluated for use in patients with FGFR2-mutated cholangiocarcinoma (CCA), or bile duct cancer, and other solid tumors. FGFR2 is one of four members of the FGFR family, a set of closely related proteins with highly similar protein sequences and properties. If the therapy and companion diagnostic are approved, FoundationOne CDx would be used to identify patients with FGFR2 fusions and select rearrangements in CCA who may be appropriate for treatment with RLY-4008.

Read more about the collaboration here.